In-Jeong Cho1, Hyeonju Jeong2, Hyuk-Jae Chang3. 1. Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, College of Medicine, Ewha Womans University, Seoul, South Korea. 2. Division of Cardiology, Department of Internal Medicine, Myungji Hospital, Goyang, South Korea. 3. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Abstract
BACKGROUND: The significance of left atrial volume index (LAVI) for predicting outcomes in patients with mitral stenosis (MS) has been unclear, even though rheumatic MS is known to be associated with left atrium enlargement and functional deterioration. HYPOTHESIS: The current study aimed to investigate the prognostic value of LAVI, based on the severity in patients with rheumatic MS. METHODS: We retrospectively reviewed 611 patients with pure rheumatic MS. The prognostic value of LAVI and the effect of MS severity on the prognostic value of LAVI for events were evaluated. The events were defined as a composite end-point that included all-cause death, heart failure admission, mitral valve replacement, percutaneous mitral valvuloplasty, and stroke. RESULTS: There were 236 (38.6%) overall events during a median follow-up of 8 months. The optimal LAVI cutoff for the prognostic threshold was 57 ml/m2 . The MS severity had a significant effect on the prognostic value of LAVI. A LAVI >57 ml/m2 was a prognostic value for events in progressive MS (hazard ratio [HR]: 2.40, 95% confidence interval [CI]: 1.41-5.40, p = .004) and in patients with severe MS (HR: 1.70, 95% CI: 1.06-2.74, p = .029), but it was not prognostic in patients with very severe MS (HR: 1.02, 95% CI: 0.56-1.84, p = .955). CONCLUSIONS: The prognostic value of LAVI varies and is dependent on the MS severity. A LAVI >57 mL/m2 was independently associated with poor outcomes in patients with progressive MS, while this association was minimized in patients with severe MS.
BACKGROUND: The significance of left atrial volume index (LAVI) for predicting outcomes in patients with mitral stenosis (MS) has been unclear, even though rheumatic MS is known to be associated with left atrium enlargement and functional deterioration. HYPOTHESIS: The current study aimed to investigate the prognostic value of LAVI, based on the severity in patients with rheumatic MS. METHODS: We retrospectively reviewed 611 patients with pure rheumatic MS. The prognostic value of LAVI and the effect of MS severity on the prognostic value of LAVI for events were evaluated. The events were defined as a composite end-point that included all-cause death, heart failure admission, mitral valve replacement, percutaneous mitral valvuloplasty, and stroke. RESULTS: There were 236 (38.6%) overall events during a median follow-up of 8 months. The optimal LAVI cutoff for the prognostic threshold was 57 ml/m2 . The MS severity had a significant effect on the prognostic value of LAVI. A LAVI >57 ml/m2 was a prognostic value for events in progressive MS (hazard ratio [HR]: 2.40, 95% confidence interval [CI]: 1.41-5.40, p = .004) and in patients with severe MS (HR: 1.70, 95% CI: 1.06-2.74, p = .029), but it was not prognostic in patients with very severe MS (HR: 1.02, 95% CI: 0.56-1.84, p = .955). CONCLUSIONS: The prognostic value of LAVI varies and is dependent on the MS severity. A LAVI >57 mL/m2 was independently associated with poor outcomes in patients with progressive MS, while this association was minimized in patients with severe MS.
Authors: Jacob E Moller; Graham S Hillis; Jae K Oh; James B Seward; Guy S Reeder; R Scott Wright; Seung W Park; Kent R Bailey; Patricia A Pellikka Journal: Circulation Date: 2003-04-14 Impact factor: 29.690
Authors: Sherif F Nagueh; Otto A Smiseth; Christopher P Appleton; Benjamin F Byrd; Hisham Dokainish; Thor Edvardsen; Frank A Flachskampf; Thierry C Gillebert; Allan L Klein; Patrizio Lancellotti; Paolo Marino; Jae K Oh; Bogdan Alexandru Popescu; Alan D Waggoner Journal: J Am Soc Echocardiogr Date: 2016-04 Impact factor: 5.251
Authors: Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano Journal: Eur Heart J Date: 2017-09-21 Impact factor: 29.983
Authors: Abdallah El Sabbagh; Yogesh N V Reddy; Sergio Barros-Gomes; Barry A Borlaug; William R Miranda; Sorin V Pislaru; Rick A Nishimura; Patricia A Pellikka Journal: J Am Heart Assoc Date: 2019-03-05 Impact factor: 5.501